

What is claimed is:

1. A stable liquid pharmaceutical formulation comprising:
 - (a) a bispecific antibody at a concentration of 2 ± 0.2 mg/ml, or 20 ± 2 mg/ml, wherein the bispecific antibody comprises a first antigen-binding domain that binds specifically to human CD20 and a second antigen-binding domain that binds specifically to human CD3, wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), and the second antigen-binding domain comprises a HCVR and a LCVR, wherein the antibody comprises a first heavy chain containing the HCVR of the first antigen-binding domain, a second heavy chain containing the HCVR of the second antigen-binding domain, and a common light chain containing the LCVR of the first and second antigen-binding domains, wherein the first heavy chain comprises residues 1-452 of the amino acid sequence of SEQ ID NO: 1, the second heavy chain comprises residues 1-448 of the amino acid sequence of SEQ ID NO: 2, and the common light chain comprises the amino acid sequence of SEQ ID NO: 3;
 - (b) a buffer comprising histidine at a concentration of from 5 mM to 15 mM;
 - (c) polysorbate at a concentration of from 0.05% to 0.15% w/v; and
 - (d) sucrose at a concentration of from 8% to 12% w/v;wherein the formulation has a pH of 5.8 ± 0.3 , and
wherein at least 95% of the antibody has native conformation after 1 month of storage at 45°C, as determined by SE-UPLC.
2. The pharmaceutical formulation of claim 1, wherein the histidine buffer comprises L-histidine and L-histidine monohydrochloride monohydrate.
3. The pharmaceutical formulation of claim 1 or 2, wherein the polysorbate is polysorbate 80.
4. The pharmaceutical formulation of claim 1 comprising:
 - (a) $2 \text{ mg/ml} \pm 0.2 \text{ mg/ml}$ antibody,
 - (b) $10 \text{ mM} \pm 1 \text{ mM}$ histidine buffer,
 - (c) $0.1\% \pm 0.05\%$ w/v polysorbate, and
 - (d) $10\% \pm 1\%$ w/v sucrose,at pH 5.8 ± 0.3 .

5. The pharmaceutical formulation of claim 4, comprising:
 - (a) 2 mg/ml antibody;
 - (b) 0.57 mg/ml histidine and 1.3 mg/ml L-histidine hydrochloride monohydrate;
 - (c) 1 mg/ml polysorbate 80; and
 - (d) 100 mg/ml sucrose.
6. The pharmaceutical formulation of claim 1 comprising:
 - (a) 20 mg/ml $\pm$ 2 mg/ml antibody,
 - (b) 10 mM $\pm$ 1 mM histidine buffer,
 - (c) 0.1% $\pm$ 0.05% w/v polysorbate, and
 - (d) 10% $\pm$ 1% w/v sucrose,at pH 5.8 $\pm$ 0.3.
7. The pharmaceutical formulation of claim 6, comprising:
 - (a) 20 mg/ml antibody;
 - (b) 0.57 mg/ml histidine and 1.3 mg/ml L-histidine hydrochloride monohydrate;
 - (c) 1 mg/ml polysorbate 80; and
 - (d) 100 mg/ml sucrose.
8. The pharmaceutical formulation of claim 4, wherein at least 98% of the antibody has native conformation after 1 month of storage at 45°C, as determined by SE-UPLC.
9. The pharmaceutical formulation of claim 6, wherein at least 96% of the antibody has native conformation after 1 month of storage at 45°C, as determined by SE-UPLC.
10. A pharmaceutical formulation comprising:
 - (a) 2 mg/ml $\pm$ 0.2 mg/ml of a bispecific antibody comprising a first antigen-binding domain that binds specifically to human CD20 and a second antigen-binding domain that binds specifically to human CD3, wherein the first antigen-binding domain comprises a HCVR and a LCVR, and the second antigen-binding domain comprises a HCVR and a LCVR, wherein the antibody comprises a first heavy chain containing the HCVR of the first antigen-binding domain, a second heavy chain containing the HCVR of the second antigen-binding domain, and a common light chain containing the LCVR of the first and second antigen-binding domains, wherein the first heavy chain comprises residues 1-452 of the amino acid sequence of SEQ ID

NO: 1, the second heavy chain comprises residues 1-448 of the amino acid sequence of SEQ ID NO: 2, and the common light chain comprises the amino acid sequence of SEQ ID NO: 3;

(b) $10 \text{ mM} \pm 1 \text{ mM}$ histidine buffer, $\text{pH } 5.8 \pm 0.2$,

(c) $0.1\% \pm 0.01\%$ w/v polysorbate 80, and

(d) $10\% \pm 1\%$ w/v sucrose,

wherein the formulation has a viscosity of less than 2 centiPoise (cP) at 20°C , as determined using a capillary viscometer, and at least 95% of the antibody has native conformation after 1 month of storage at 45°C , as determined by SE-UPLC.

11. The pharmaceutical formulation of claim 10, comprising:

(a) 2 mg/ml antibody;

(b) 0.57 mg/ml histidine and 1.3 mg/ml L-histidine hydrochloride monohydrate;

(c) 1 mg/ml polysorbate 80; and

(d) 100 mg/ml sucrose.

12. A pharmaceutical formulation comprising:

(a) $20 \text{ mg/ml} \pm 2 \text{ mg/ml}$ of a bispecific antibody comprising a first antigen-binding domain that binds specifically to human CD20 and a second antigen-binding domain that binds specifically to human CD3, wherein the first antigen-binding domain comprises a HCVR and a LCVR, and the second antigen-binding domain comprises a HCVR and a LCVR, wherein the antibody comprises a first heavy chain containing the HCVR of the first antigen-binding domain, a second heavy chain containing the HCVR of the second antigen-binding domain, and a common light chain containing the LCVR of the first and second antigen-binding domains, wherein the first heavy chain comprises residues 1-452 of the amino acid sequence of SEQ ID NO: 1, the second heavy chain comprises residues 1-448 of the amino acid sequence of SEQ ID NO: 2, and the common light chain comprises the amino acid sequence of SEQ ID NO: 3;

(b) $10 \text{ mM} \pm 1 \text{ mM}$ histidine buffer, $\text{pH } 5.8 \pm 0.2$,

(c) $0.1\% \pm 0.01\%$ w/v polysorbate 80, and

(d) $10\% \pm 1\%$ w/v sucrose,

wherein the formulation has a viscosity of less than 2 centiPoise (cP) at 20°C , as determined using a capillary viscometer, and at least 95% of the antibody has native conformation after 1 month of storage at 45°C , as determined by SE-UPLC.

13. The pharmaceutical formulation of claim 12, comprising:

(a) 20 mg/ml antibody;

- (b) 0.57 mg/ml histidine and 1.3 mg/ml L-histidine hydrochloride monohydrate;
- (c) 1 mg/ml polysorbate 80; and
- (d) 100 mg/ml sucrose.

14. The pharmaceutical formulation of any one of claims 1-13, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2, and the common light chain comprises the amino acid sequence of SEQ ID NO: 3.

15. A single dose vial comprising the pharmaceutical formulation of claim 10 or 11, wherein the vial contains from 2 mg to 2.5 mg of the bispecific antibody.

16. The single dose vial of claim 15, wherein the vial contains 2 mg of the bispecific antibody.

17. A single dose vial comprising the pharmaceutical formulation of claim 12 or 13, wherein the vial contains from 80 mg to 90 mg of the bispecific antibody.

18. The single dose vial of claim 17, wherein the vial contains 80 mg of the bispecific antibody.

19. A single dose vial comprising the pharmaceutical formulation of claim 12 or 13, wherein the vial contains from 320 mg to 360 mg of the bispecific antibody.

20. The single dose vial of claim 19, wherein the vial contains 320 mg of the bispecific antibody.